Company: VERA
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029969
Chunk: 157

Company: Vera Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 157
---
 $
        88,257

        Vested and expected to vest as of December 31, 2024

        6,611,797

        $
        16.44

        8.11

        $
        172,630

       The aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $46.8 million. The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and 2023, was $19.65 per share and $5.92 per share, respectively.In August 2024, the Company repurchased 4,450 unvested shares that were previously outstanding due to a stock option that was early exercised. The unvested shares were repurchased at the original exercise price of $2.8968 per share.Award ActivityThe Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of the Company’s Class A common stock. The following table shows RSU activity for the period ending December 31, 2024:

116

        Number of Shares

        Weighted-Average Grant Date Fair Value per Share

        Unvested balance at December 31, 2023

        131,679

        $
        18.36

        Granted

        713,812

        29.67

        Vested

        (111,396
        )

        19.03

        Cancelled and forfeited

        (37,207
        )

        22.33

        Unvested balance at December 31, 2024

        696,888

        $
        29.63

       Stock-Based Compensation Expense The following tables summarize the stock-based compensation expense for stock options and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company’s statements of operations and comprehensive loss for the years ended December 31, 2024 and 2023 (in thousands): 

        Year Ended December 31,

        2024

        2023

        Research and development
         
        $
        8,537

        $
        4,845

        General and administrative

        12,265

        6,648

        Total stock-based compensation expense
         
        $
        20,802

        $
        11,493